{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:40:36Z","timestamp":1785454836218,"version":"3.56.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This Phase I, randomized, multicenter, open\u2010label, parallel\u2010group, single\u2010dose study assessed the relative bioavailability of the anti\u2013interleukin\u20105 antibody depemokimab (100\u00a0mg) when administered subcutaneously via either a safety syringe device (SSD) or an autoinjector (AI). Healthy adult participants were randomized I:I to SSD or AI treatment arms and I:I:I to the injection site (upper arm, abdomen, or thigh). Participants were followed up for 30 weeks; blood samples were collected for pharmacokinetic (PK) assessment before dosing on Day 1 and up to Week 26. Depemokimab concentration profile as measured by plasma maximum concentration (C<jats:sub>max<\/jats:sub>), the area under the concentration\u2013time curve from time zero extrapolated to infinity (AUC<jats:sub>0\u2010inf<\/jats:sub>), PK parameters, immunogenicity, and safety were assessed. Overall, 140 participants were enrolled (n\u00a0=\u00a070 per arm). Mean plasma concentration\u2010time profiles of depemokimab were similar in both treatment arms, regardless of the injection site, adjusted geometric mean AI:SSD ratios for C<jats:sub>max<\/jats:sub> and AUC<jats:sub>0\u2010inf<\/jats:sub> were 1.03 and 1.03, respectively, with all 90% confidence intervals within the bioequivalence bounds of 0.80\u20101.25. PK parameters were comparable across treatment arms. Treatment\u2010related adverse events were reported in 19% of SSD and 20% of AI participants, with headache being the most common across both arms; no adverse events led to study withdrawal. These results support the use of either SSD or AI for subcutaneous administration of depemokimab.<\/jats:p>","DOI":"10.1002\/cpdd.1506","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T06:13:35Z","timestamp":1738131215000},"page":"190-199","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single\u2010Dose Study"],"prefix":"10.1002","volume":"14","author":[{"given":"Stein","family":"Schalkwijk","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Modelling and Simulation GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecchin","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modelling and Simulation GSK  Stevenage Hertfordshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusmita","family":"Sen","sequence":"additional","affiliation":[{"name":"Biostatistics GSK  Bengaluru India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Choi","sequence":"additional","affiliation":[{"name":"Global Clinical Development GSK  Ottawa Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Biomarker and Bioanalytical Platform GSK  Collegeville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Min","sequence":"additional","affiliation":[{"name":"Clinical Research Respiratory GSK  Waltham MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Spears","sequence":"additional","affiliation":[{"name":"Clinical Research Unit PPD  Austin TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032506"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S198953"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02671-2"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2019.1587043"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S170636"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S154181"},{"key":"e_1_2_11_10_1","first-page":"1061","article-title":"Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self\u2010injection experience","volume":"8","author":"Demary W","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.726"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1663428"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253048"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00245-0"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1604745"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1630641"},{"issue":"63","key":"e_1_2_11_17_1","article-title":"Mepolizumab self\u2010administration via autoinjector and prefilled syringe: the qualitative patient experience","volume":"54","author":"Evitt L","year":"2019","journal-title":"Eur Respir J"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1390473"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.07.017"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.04.015"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:40:26Z","timestamp":1741873226000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cpdd.1506"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1506","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2024-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}